| Migraine Disorders
Qulipta vs VYEPTI
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Qulipta vs Vyepti with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyepti has a higher rate of injection site reactions vs Qulipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyepti but not Qulipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Qulipta
Vyepti
At A Glance
Oral
Daily
CGRP receptor antagonist
IV infusion
Every 3 months
CGRP antagonist
Indications
- Migraine Disorders
- Migraine Disorders
Dosing
Migraine Disorders (episodic) 10 mg, 30 mg, or 60 mg taken once daily orally, with or without food.
Migraine Disorders (chronic) 60 mg taken once daily orally, with or without food.
Migraine Disorders 100 mg by IV infusion every 3 months; some patients may benefit from 300 mg by IV infusion every 3 months.
Contraindications
- History of hypersensitivity to atogepant or any of the components of QULIPTA (reactions have included anaphylaxis and dyspnea)
- Serious hypersensitivity to eptinezumab-jjmr or any excipient, including anaphylaxis and angioedema
Adverse Reactions
Most common (>=4%) Nausea, constipation, fatigue/somnolence
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Hypersensitivity (anaphylaxis, dyspnea, rash, pruritus, urticaria, facial edema), hypertension, Raynaud's phenomenon
Most common (>=2%) nasopharyngitis, hypersensitivity reactions
Postmarketing anaphylaxis, fatigue, hypertension, Raynaud's phenomenon
Pharmacology
Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it blocks CGRP receptor signaling implicated in migraine pathophysiology and is indicated for preventive treatment of migraine in adults.
Eptinezumab-jjmr is a humanized IgG1 monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, thereby preventing CGRP-mediated effects relevant to migraine.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Qulipta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Vyepti
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Qulipta
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Vyepti
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Qulipta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Vyepti
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
QuliptaView full Qulipta profile
VyeptiView full Vyepti profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.